Adverse reactions
Disorders on the side of the immune system Uncommon Hypersensitivity reaction Rarely Anaphylactic reaction* Metabolic and nutritional disorders Very often Absence of appetite (decreased appetite) Disorders on the side of the nervous system Very often Crying, drowsiness Yes Frequently Abnormal crying (tremorous crying) Rarely Sudoma with or without elevation of body temperature Temperature* Very rarely Hypotonic reactions or hypotonic-hyporesponsive syndrome (HHE) Disorders on the side of the scolio-intestinal tract Very often Vomiting Often Diarrhea Disorders on the side of the skin and axillary tissue Rarely Visip Underlying disorders and reactions at the site of drug administration Very often Pain at the site in Ections, erythema at the site of injection, swelling at the site of injectionGraciousness
Hyperthermia (elevated body temperature ≥ 38.0°C)
Often Strengthened at the site of injection Uncommon Creation of a node at the site of injectionHyperthermia (elevated body temperature ≥ 39.6°C)
Rarely Extensive endings†* Unnecessary reactions recorded based on spontaneous reporting data.
† Div. divided (s).
c) Description of some unusual reactions
Extensive marking of the ending. Extensive reactions at the site of injection (> 50 mm) have been reported in children, including extensive swelling of the end that can expand from the site of injection beyond one or two adjacent angles iv. These reactions begin in the first 24-72 years after vaccination and may be accompanied by symptoms such as erythema, hot local changes in skin temperature, tenderness and pain at the site of injection, and discover on their own over a period of 3-5 days. The risk of its development lies in the number of first doses of vaccines in order to remove the acellular cough component, which has a higher risk characteristic after the 4th and 5th doses.
d) Potential adverse reactions (adverse reactions that were not observed to the drug itself after administration of the Hexaxim vaccine, but were observed after exposure to other vaccines, which may be one or the other more about the preparation of components that are included in the Hexaxim vaccine warehouse)
Relaxation on the side of the nervous system
- It was reported about the development of brachial neuritis and Guillain-Barré syndrome after the vaccine was stagnated instead of the right toxoid.
- It was reported about the development of peripheral neuropathy (polyradiculoneuritis, facial nerve palsy), neuritis of the visual nerve, demyelinization in the central nervous system and demyelinating diseases of the central nervous system. (multiple sclerosis) after stagnation of the vaccine instead of hepatitis B antigen.
- Encephalopathy/encephalitis.
Relax on the side of the respiratory system, chest and mediastinum
Apnea in even premature infants is unheard of (the term is ≤ 28 years of age) (section “Peculiarities of congestion”).
Underlying disorders and reactions at the injection site
After splintering with vaccines that avenge the Haemophilus influenzae
type b, there may be a bumping reaction that expands to one or two lower ends. This reaction is important to watch out for after the first injection and persists for the first few years after for wood chips. Symptoms associated with this reaction may include cyanosis, redness, transient purpura, and excessive crying. All these items may appear on their own and without leaving a trace within 24 years.
If you have any unexpected reactions that are not indicated in this overflow, please tell your doctor.
Term of attribution
3 rocks.
Umovi sberіgannya
Store at a temperature of 2 to 8 ºС (in the refrigerator). Do not freeze.
Protect from light. Keep out of the reach of children.
Package
Suspension for injections of 0.5 ml (1 dose) in front-line syringes with 1 (or 2) rounded heads, 1 syringe in a cardboard package at a time with instructions for drying.
Suspension for injections of 0.5 ml (1 dose) in front-line syringes with 1 (or 2) rounded heads, 10 syringes in a cardboard package at a time with instructions for setting.
Suspension for injection, 0.5 ml (1 dose) in bottles, 10 bottles in a cardboard package at a time with instructions for drying.
Vaccination
In order for vaccination to be carried out correctly, it is necessary to adhere to the calendar of preventive vaccinations, which was developed by the Ministry of Health of the Republic of Belarus.
We carry out the vaccination procedure ONLY IN ACCORDANCE with the NATIONAL CALENDAR of preventive vaccinations and the LIST OF PREVENTIVE VACCINATIONS ACCORDING TO EPIDEMIC INDICATIONS
, approved by Resolution of the Ministry of Health of the Republic of Belarus dated May 17, 2018 No. 42 “On preventive vaccinations” (registered in the National Center for Legal Information of the Republic of Belarus, June 12, 2018, 8/33221). Regardless of our attitude to the WHO recommendations and the methods of use of the drug indicated in the annotation, we strictly adhere to the above regulatory document.
Sanitary norms and rules “Sanitary and epidemiological requirements for transportation, storage and use of immunobiological medicines, carrying out preventive vaccinations, identification, registration and investigation of adverse reactions after preventive vaccinations” approved by Resolution No. 114 of the Ministry of Health of the Republic of Belarus “02” December 2013 determine the duration of storage and permissible temperature conditions at individual levels of the cold chain (Appendix 2 to these Sanitary Norms and Rules). At the fourth level of the cold chain (health care and other organizations of all forms of ownership that have vaccination rooms), this duration is no more than 1 month. For our part, we do not purchase or store the vaccine in stock for more than 1.5 - 2 weeks. Due to the requirements for the storage and transportation of vaccines, certain specified sanitary norms and rules, we DO NOT SELL, DO NOT RESERVE VACCINES or store them for specific patients, and do not vaccinate with a drug that was purchased by the client somewhere independently.
Before vaccination, it is necessary to take tests (general urine test and general blood test) and undergo a doctor’s examination! You must have an extract of vaccinations from your outpatient card (or the card itself).
Before vaccination, a pediatrician examines the child, studies medical documentation (test results and extract) and decides on the possibility of carrying out the procedure. If there are medical reasons, vaccination may be refused. In this case, the client must pay the cost of the inspection according to the price list valid at the time the service is provided. DRAW YOUR ATTENTION TO! Consultation on any other issues is not provided as part of the pre-vaccination examination. To draw up an individual vaccination schedule, provide advice on other issues regarding the child’s health, obtain certificates, etc., a separate appointment is required.
DRAW YOUR ATTENTION TO! Changes in prices for immunization services occur with an increase/decrease in the cost of immunobiological drugs, which is completely determined by the vaccine supplier and does not depend in any way on our center. Any discounts and promotions DO NOT APPLY to this type of service!
RECOMMENDATIONS FOR PARENTS DURING THE POST-VACCINATION PERIOD: - Do not go home immediately after vaccination: the drug administered to the child adapts in the body, so it is recommended to sit in the center for 15-30 minutes. — At home, monitor your baby, his general condition, temperature, and stay in touch with your pediatrician. — Limit your child’s contact with strangers. — Avoid interaction of the injection site with water.
Vaccination Infanrix 77.59 rub.
Infanrix is a vaccine (manufactured in Belgium) used to prevent tetanus, whooping cough, and diphtheria.
Infanrix, according to the National Preventive Vaccination Calendar of the Republic of Belarus, is indicated for primary vaccination against diphtheria, tetanus and whooping cough in children from 3 months of age and for revaccination of children who were previously immunized with three doses of acellular pertussis-diphtheria-tetanus or whole-cell pertussis-diphtheria -tetanus vaccine.
Vaccination Prevenar RUB 13,206.34
Prevenar 13 is a vaccine (country of origin - Ireland) for the prevention of pneumococcal infections.
Contains 13 active substances, which are pneumococcal polysaccharides obtained from the gram-positive bacteria Streptococcus pneumoniae, individually conjugated to the diphtheria carrier protein CRM197, and adsorbed on aluminum phosphate.
The vaccine is used:
-
in children aged 6 weeks to 17 years
to protect against diseases such as meningitis (inflammation of the lining of the brain), sepsis or bacteremia (presence of bacteria in the blood), pneumonia (lung infection), and infectious diseases ear;
- in adults aged 18 years and older
to prevent diseases such as pneumonia (a lung infection), sepsis or bacteremia (the presence of bacteria in the blood) and meningitis (inflammation of the lining of the brain) caused by 13 serotypes of the bacteria Streptococcus pneumoniae.
Infants between 7 and 11 months of age should receive two vaccinations.
The interval between vaccinations should be at least one month.
The third vaccination will be carried out in the second year of life. Children aged 12 to 23 months should receive two vaccinations
.
The interval between vaccinations should be at least two months. Children and adolescents ages 2 to 17 should receive one vaccine. Adults must receive one vaccine.
Vaccination Hexaxim RUB 162.98
Hexaxim is a vaccine (manufactured in France) used for the prevention of diphtheria, tetanus, whooping cough, hepatitis B and diseases caused by Haemophilus influenzae type b.
For primary vaccination and revaccination of children aged 6 weeks and older.
The drug should be used according to the national vaccination schedule. Primary vaccination consists of administering 2 doses of 0.5 ml vaccine (with an interval between doses of at least 8 weeks) or 3 doses of 0.5 ml vaccine (with an interval between doses of at least 4 weeks) in accordance with with official recommendations.
Vaccination Adasel RUB 111.31
Vaccine "Adasel" (country of origin - Canada)
is the first
combined vaccine for revaccination against whooping cough, diphtheria and tetanus registered in the Republic of Belarus. The immunization scheme corresponds to the National Calendar of Preventive Vaccinations of the Republic of Belarus.
The Adasel vaccine is intended for: - revaccination in children aged 6 years; - in adolescents at 16 years of age; — then every 10 years for adults up to 64 years of age.
Vaccination Infanrix Hexa RUB 133.78
Infanrix Hexa is a vaccine (manufactured in Belgium) used for the prevention of tetanus, whooping cough, diphtheria, hepatitis B, Haemophilus influenzae, and polio.
According to the National Calendar of Preventive Vaccinations of the Republic of Belarus, the course of primary vaccination consists of 3 doses of vaccine administered at 2, 3, and 4 months, revaccination is carried out once at 18 months.
Vaccine TikoVak RUB 104.72
Vaccine TicoVac produced by Pfizer Menufecchuring (Belgium)
.
Indicated for active (preventive) immunization of people over 16 years of age against tick-borne encephalitis (TBE). The primary vaccination schedule is the same for everyone and consists of three vaccinations.
The first and second doses should be administered 1 to 3 months apart. The third dose should be administered 5 to 12 months after the second dose. After the third dose, protection is expected to continue for at least 3 years. The first revaccination is carried out 3 years after the third dose of the primary series. Subsequent revaccinations are every 5 years (revaccination of people over 60 years of age is carried out every 3 years).
Vaccine Tikovak Junior 99.75 rub.
Vaccine TicoVac Junior produced by Pfizer Menufecchuring (Belgium)
.
Indicated for active (preventive) immunization of children aged 1 to 15 years against tick-borne encephalitis
(TBE).
The primary vaccination schedule is the same for everyone and consists of three vaccinations.
The first and second doses should be administered 1 to 3 months apart. The third dose should be administered 5 to 12 months after the second dose. After the third dose, protection is expected to continue for at least 3 years. The first revaccination is carried out 3 years after the third dose of the primary series. Subsequent revaccinations are every 5 years.
Infanrix Hexa
If the NCPP is strictly followed, Infanrix Hexa is administered only once, at the age of 6 months (when scheduled administration of both all five components of the Pentaxim vaccine and the third final dose of the hepatitis B vaccine is required). But in case of violation of the vaccination schedule according to the national calendar (for example, when the first vaccination against hepatitis B was not administered in the maternity hospital, and the second at the age of one month), the doctor can replace Pentaxim with Infanrix Hexa, so as not to administer the drug against hepatitis B by a separate injection.
The Infanrix Hexa vaccine contains six components and protects the child from the following diseases:
- whooping cough;
- diphtheria;
- tetanus;
- polio;
- infections caused by Haemophilus influenzae type b;
- viral hepatitis B is a viral (contagious, transmitted through blood and other biological fluids) liver disease, which is dangerous both in itself (jaundice, abdominal pain, malaise), and by becoming chronic and with complications (can lead to cirrhosis, cancer liver and death).
Combining several drugs in one is an advantage of Infanrix Hexa (as well as Pentaxima).
The Infanrix Hexa vaccine, like Pentaxim, contains an acellular pertussis component and is better tolerated than Russian vaccines.
If Infanrix Hexa was not administered within the time period recommended by the national calendar, the vaccine is administered at the age of application for vaccination. If one or more doses were previously administered and then followed by a long break, restarting the vaccine series is not required; the missing doses must be administered as soon as possible, observing the minimum intervals between them.
The Infanrix Hexa vaccine is not administered earlier than 2 months and later than 3 years of age.
Tolerability of the vaccine is average: in the evening after vaccination, approximately every tenth child may feel unwell, the temperature may rise to 38 °C, and the injection site may be slightly sore. Around one in 20 people may experience a fever of up to 39°C, severe redness and swelling at the injection site, and malaise. These reactions are safe , resolve within 1–3 days and require only paracetamol or Nurofen to relieve symptoms. The vaccine does not contain live components, so there are no delayed adverse reactions to the vaccine.
Vaccination calendar for children from 0 to 7 years old
Graphic calendar of vaccinations for children from birth to 7 years of age, indicating the timing of vaccine administration according to Russian rules. Source:
CDC calendar
Editorial team:
pediatrician Sergei Butriy
Vaccination against meningococcal infection
Unfortunately, it is not included in the National Calendar of Preventive Vaccinations (and therefore is not available for free), but is included in the Moscow calendar and in the calendars of some developed countries. However, there is no international consensus on the optimal age of administration of Menactra and the frequency of revaccination. In the United States, the vaccine is administered twice, at 11 and 16 years of age; in England, separate components of the vaccine are introduced at a very early age - each country is based on its level of incidence at different ages and its budget for medicine. In Moscow, it is recommended to administer the vaccine “before entering children’s institutions.”
Meningococcus is a bacterial pathogen that has several serotypes, each of which is designated by a Latin letter or a letter and then a number. There is no cross immunity between them; a separate vaccine has to be developed and administered against each serotype. At first they were administered separately, separately against meningococcus group A (MenA), separately against meningococcus group C (MenC), etc. Menactra became a vaccine that combined protection against 4 of the 5 most dangerous serotypes of meningococcus: A, C, Y and W-135. At the time the vaccine was developed, a vaccine against group B meningococcus had not yet been invented. Now it has appeared, but is not available in Russia.
The Menactra vaccine is approved from 9 months of age to 55 years of age. When administered before 2 years, two doses are required with an interval of at least 3 months; when administered after 2 years, only one dose is required to create immunity for 5 years. At the Rassvet clinic, we recommend vaccination of children from 9 months, followed by revaccination every 5 years, or at least in adolescence. We recommend vaccination for adults only if there is a high risk of infection, after consultation with a doctor.
We also recommend receiving the Bexsero (meningococcal group B) vaccine if you are traveling to European countries where it is available, twice, 2 months apart. Unfortunately (since the vaccine is not available in the Russian Federation), not all families from Russia can follow this recommendation.
The Menactra vaccine has average tolerability: on the first day after vaccination, approximately every tenth vaccinated person may experience swelling, pain and swelling of the tissues at the injection site, general malaise, and a temperature of up to 38 °C. This reaction will last 1–3 days and will go away on its own . Ibuprofen or paracetamol can be used to relieve symptoms. The vaccine is not live, so there are no delayed reactions to it.
Vaccination calendar for children from 0 to 7 years old
Graphic calendar of vaccinations for children from birth to 7 years of age, indicating the timing of vaccine administration according to Russian rules. Source:
CDC calendar
Editorial team:
pediatrician Sergei Butriy
